Dashboard
1
Poor Management Efficiency with a low ROCE of 3.24%
- The company has been able to generate a Return on Capital Employed (avg) of 3.24% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 9.48% and Operating profit at 28.05% over the last 5 years
4
With a fall in Net Sales of -11.81%, the company declared Very Negative results in Mar 25
5
With ROE of 5.38%, it has a fair valuation with a 2.22 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,773 Million (Mid Cap)
41.00
NA
1.34%
0.68
5.38%
2.22
Revenue and Profits:
Net Sales:
1,465 Million
(Quarterly Results - Jun 2025)
Net Profit:
28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.51%
0%
0.51%
6 Months
-11.37%
0%
-11.37%
1 Year
10.96%
0%
10.96%
2 Years
22.75%
0%
22.75%
3 Years
45.7%
0%
45.7%
4 Years
38.5%
0%
38.5%
5 Years
7.21%
0%
7.21%
Shandong Lukang Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.48%
EBIT Growth (5y)
28.05%
EBIT to Interest (avg)
2.60
Debt to EBITDA (avg)
4.98
Net Debt to Equity (avg)
0.69
Sales to Capital Employed (avg)
0.87
Tax Ratio
4.32%
Dividend Payout Ratio
30.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.24%
ROE (avg)
6.64%
Valuation key factors
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
2.22
EV to EBIT
42.38
EV to EBITDA
16.54
EV to Capital Employed
1.73
EV to Sales
1.89
PEG Ratio
NA
Dividend Yield
1.34%
ROCE (Latest)
4.08%
ROE (Latest)
5.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,465.20
1,661.30
-11.80%
Operating Profit (PBDIT) excl Other Income
162.70
188.90
-13.87%
Interest
16.90
16.50
2.42%
Exceptional Items
-0.10
0.00
Consolidate Net Profit
28.30
82.30
-65.61%
Operating Profit Margin (Excl OI)
38.50%
49.70%
-1.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -11.80% vs 7.17% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -65.61% vs 60.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,178.50
6,093.00
1.40%
Operating Profit (PBDIT) excl Other Income
694.70
659.70
5.31%
Interest
75.40
79.20
-4.80%
Exceptional Items
0.80
0.30
166.67%
Consolidate Net Profit
408.30
256.80
59.00%
Operating Profit Margin (Excl OI)
47.40%
45.50%
0.19%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.40% vs 9.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 59.00% vs 79.45% in Dec 2023
About Shandong Lukang Pharmaceutical Co., Ltd. 
Shandong Lukang Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






